Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia

Inclusion Criteria: For patients with solid tumors: * documented cKit-positive neoplasms * Patient must have progressive disease as defined by any of the following: * SCLC: patient has progressed after at least 1 prior therapy * GIST : patient has relapsed or has refractory disease, and no further approved effective therapeutic option exists * Patients with other cKit-positive solid tumors: patient has progressed after at least one prior line of therapy and no further approved effective therapeutic option exists * Patient has measurable disease as per RECIST v1.1 criteria For patients with AML: * documented cKit-positive acute myelogenous leukemia * Consent to newly obtained bone marrow aspirate * Patient must have progressive disease defined as relapsed or refractory non-PML AML following standard therapy or for whom no effective therapy exists. * Blast count \< 50,000/mm3 Exclusion Criteria: For patients with solid tumors: * Patient has central nervous system (CNS) metastatic involvement unless the CNS metastases have been previously treated and the patient is clinically stable and on a stable dose of corticosteroids for at least 4 weeks prior to enrollment. * Patient has the presence of other clinically significant hematologic, cardiac, respiratory, gastrointestinal, renal, hepatic or neurological conditions. * Patient has a history of serious allergic reactions, which in the opinion of the investigator may pose an increased risk of serious infusion reactions * Patient has been previously treated with cKit directed antibodies * Pregnant or nursing women For patients with AML: * Patient has received prior allogeneic bone marrow transplant (BMT). * Patient has the presence of other clinically significant cardiac, respiratory, gastrointestinal, renal, hepatic or neurological disease * Patient has a history of serious allergic reactions, which in the opinion of the investigator may pose an increased risk of serious infusion reactions * Patient has been previously treated with cKit directed antibodies * Pregnant or nursing women